Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKSE: 2315) is trading at HK$67.75, about ₹829 at today's HKD/INR rate, as of 29 Sep 2026, 11:59 PM ET, up 4.71% today. Indian residents can buy Biocytogen Pharmaceuticals (Beijing) from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
HK$65.25
Today's high
HK$69.95
52 week low
HK$21.54
52 week high
HK$75.30
2315 opened at HK$65.40, closed previously at HK$64.70, and has traded between HK$21.54 and HK$75.30 over the past 52 weeks.
About
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., established in 2009 with its main office in Beijing, China, operates as a global biotechnology firm. Its core business involves the international research and development of antibody-based treatments. The company's drug development portfolio currently features a dozen key product candidates; specifically, two are actively progressing through multi-regional Phase II clinical trials, while another pair is in Phase I clinical assessments. Their therapeutic focus spans critical health areas such as oncology, autoimmune disorders, inflammatory conditions, metabolic diseases, and other ailments. Supporting these pharmaceutical ventures, the broader Beijing Biocytogen Co., Ltd. group, which commenced operations in 2008, also in Beijing, specializes in the creation and large-scale distribution of genetically modified animal models. This group provides comprehensive preclinical research services, leveraging its expertise in advanced gene-humanized models, patient-derived xenograft (PDX) models, and human immune system reconstituted models. Their extensive catalog includes a diverse array of specialized gene-edited mice and rats – for example, B-NDG mice, various Cre and knockout (KO) lines (like B-p53 KO and B-ApoE KO), knock-in (KI) models, B-hFcgrt (FcRn) mice, in addition to genome-edited human embryonic stem cells (hESC) and luciferase-reporter stable tumor cell lines. Furthermore, this overarching Biocytogen entity has cultivated an advanced platform dedicated to antibody discovery and development. It offers specialized pharmacology services across vital domains including tumor immunology, general oncology, autoimmune research, and both in vivo and in vitro pharmacological evaluations. The group also makes its products accessible through online sales channels. Beyond its primary location in Beijing, China, the company maintains additional facilities in Haimen, Jiangsu, and Shanghai, China, as well alongside international branches in Heidelberg, Germany, and Boston, United States.
Key statistics
Avg. volume
1.86M
Market cap
HK$27.47B
P/E Ratio
68.07
Price-to-sales ratio
13.80
Enterprise value
CN¥11.71B
Free cash flow yield
2.23%
Debt-to-equity ratio
0.36
Return on equity
7.96%
ROIC
8.49%
Beta
0.14
Dividend yield
0.00%
Last dividend
HK$0.00
Financial overview
Revenue
CN¥1.38B
Earnings per share
CN¥0.43
Free cash flow
CN¥282.43M
Net profit margin
21.54%
Gross margin
77.06%
EBITDA
CN¥419.49M
Revenue growth
40.63%
Similar securities
This is not an investment recommendation
How to buy Biocytogen Pharmaceuticals (Beijing) from India
Indian residents can buy Biocytogen Pharmaceuticals (Beijing) shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to HKD.
Search for Biocytogen Pharmaceuticals (Beijing) and place an order
Find Biocytogen Pharmaceuticals (Beijing) by name or by its ticker, 2315, and choose an order type. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. Biocytogen Pharmaceuticals (Beijing) trades 7:00 am – 1:30 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Biocytogen Pharmaceuticals (Beijing) position in HKD and INR. Biocytogen Pharmaceuticals (Beijing) pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Biocytogen Pharmaceuticals (Beijing) from India
Trading and taxes when buying Biocytogen Pharmaceuticals (Beijing) from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm HKT
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneBiocytogen Pharmaceuticals (Beijing) does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy Biocytogen Pharmaceuticals (Beijing) stock?
Yes. Biocytogen Pharmaceuticals (Beijing) (2315) has been listed on the Hong Kong Stock Exchange since 2022, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to HKD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one Biocytogen Pharmaceuticals (Beijing) share cost in rupees?
One Biocytogen Pharmaceuticals (Beijing) share is HK$67.75 — about ₹829 at an HKD/INR rate of 12.24 on 29 Sep 2026. Both the Biocytogen Pharmaceuticals (Beijing) price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Biocytogen Pharmaceuticals (Beijing) from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
What is the minimum I can buy of Biocytogen Pharmaceuticals (Beijing)?
Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
How are gains on Biocytogen Pharmaceuticals (Beijing) shares taxed in India?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the HKD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Biocytogen Pharmaceuticals (Beijing) price. Paasa issues a capital-gains statement for your return.
Does Biocytogen Pharmaceuticals (Beijing) pay a dividend?
No. Biocytogen Pharmaceuticals (Beijing) does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Biocytogen Pharmaceuticals (Beijing) from India?
The Hong Kong Stock Exchange trades 7:00 am – 1:30 pm IST in Indian time. It also halts for lunch, 9:30 am – 10:30 am IST. Orders can only execute during that window.
Is Biocytogen Pharmaceuticals (Beijing) a Hong Kong SAR China company, and does that change how it is taxed?
Biocytogen Pharmaceuticals (Beijing) trades on the Hong Kong Stock Exchange in HKD, but the company is domiciled in China. Biocytogen Pharmaceuticals (Beijing) trades as an ordinary share listed directly in Hong Kong, not a depositary receipt. Your India-side capital-gains treatment is the same either way.
Do I have to declare Biocytogen Pharmaceuticals (Beijing) shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Biocytogen Pharmaceuticals (Beijing) holding, its cost and its closing value.
How do I sell Biocytogen Pharmaceuticals (Beijing) and bring the money back to India?
You sell during market hours (7:00 am – 1:30 pm IST) and the proceeds settle in HKD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.